Compare Goodyear Tire & Rubber Co (GT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Merck & Co., Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $5.95 (market cap $1.75B), while Merck & Co., Inc. trades at $132.97 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 183.9× Goodyear Tire & Rubber Co's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | MRK | |
|---|---|---|
Market Cap | $1.75B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $131.84 |
52-Week Low | $5.58 | $77.60 |
Enterprise Value | $9.11B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $5.955, down 1.24% on the day, with a bearish technical signal and mixed analyst sentiment. The company reported a Q2 2026 loss of $0.61 per share, beating expectations but reflecting ongoing volume pressure. Revenue trends show a decline from $20.8B in 2022 to $17.7B projected for 2026, with negative net income margins. Valuation metrics appear attractive with P/E of 4.69 and P/B of 0.62, but profitability remains challenged with ROE at -63.93%.
The outlook remains cautious as Goodyear faces persistent volume declines and competitive pressures, though cash flow improvements and Asia Pacific gains provide some support. Investment opportunity exists in the deeply discounted valuation if operational turnaround succeeds, but risks include continued market share erosion and high debt levels. Analyst consensus shows 34.6% buy ratings with 50% recommending hold, indicating Wall Street's wait-and-see approach.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
